Pharmacogenomic Testing in Child and Adolescent Psychiatry: An Evidence-Based Review
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Significant advances have been made in the application of pharmacogenomic testing for the treatment of patients with psychiatric disorders. Over the past decade, a number of studies have evaluated the utility of pharmacogenomic testing in pediatric patients with psychiatric disorders. The evidence base for pharmacogenomic testing in youth with depressive and anxiety disorders as well as attention/deficit hyperactivity disorder (ADHD) is reviewed in this paper. General pharmacogenomic principles are summarized and functional polymorphisms in P450 enzymes (and associated metabolizer phenotypes), the serotonin transporter promoter polymorphisms, serotonin 2A receptor genes (e.g., HT2AR) and catecholamine pathway genes (e.g., COMT) are reviewed. These commonly tested pharmacogenomic markers are discussed with regard to studies of drug levels, efficacy and side effects. The translation of pharmacogenomics to individualized/precision medicine in pediatric patients with ADHD, anxiety and depressive disorders has accelerated; however, its application remains challenging given that there are numerous divergent pathways between medication/medication dose and clinical response and side effects. Nonetheless, by leveraging variations in individual genes that may be relevant to medication metabolism or medication target engagement, pharmacogenomic testing may have a role in predicting treatment response, side effects and medication selection in youth with ADHD, depressive and anxiety disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Serotonin transporter genetic variation and the response of the human amygdala.
Hariri, A. R., Mattay, V. S., Tessitore, A., Kolachana, B., Fera, F., Goldman, D., Egan, M. F., & Weinberger, D. R. (2002) · Science · doi:10.1126/science.1071829 · Cited by 2,340
Allelic Variation of Human Serotonin Transporter Gene Expression
Heils, A., Teufel, A., Petri, S., Stöber, G., Riederer, P., Bengel, D., & Lesch, K. P. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66062621.x · Cited by 2,221
Lachman, H. M., Papolos, D. F., Saito, T., Yu, Y.-M., Szumlanski, C. L., & Weinshilboum, R. M. (1996) · Pharmacogenetics · doi:10.1097/00008571-199606000-00007 · Cited by 1,788
Mattay, V. S., Goldberg, T. E., Fera, F., Hariri, A. R., Tessitore, A., Egan, M. F., Kolachana, B., Callicott, J. H., & Weinberger, D. R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931309100 · Cited by 893 · cited 1×
“Similarly, studies have found an association between the val/val genotype and a more favorable response to amphetamines.(34)”
Serretti, A., Kato, M., De Ronchi, D., & Kinoshita, T. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001926 · Cited by 529 · cited 1×
“0001).(19) Other variants in this gene may also be associated with expression of the transporter, adverse reactions and response to SSRIs.”
Wagner, K. D., Berard, R., Stein, M. B., Wetherhold, E., Carpenter, D. J., Perera, P., Gee, M., Davy, K., & Machin, A. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1153 · Cited by 240 · cited 1×
“This has been hypothesized to underlie the poor tolerability of this medication in pediatric patients with depression and anxiety disorders.(2) On the other hand, for medications that must be activated through a cytochrome P450 (e.”
The Effect of Paroxetine on 5-HT2A Receptors in Depression: An [18F]Setoperone PET Imaging Study
Meyer, J. H., Kapur, S., Eisfeld, B., Brown, G. M., Houle, S., DaSilva, J., Wilson, A. A., Rafi-Tari, S., Mayberg, H. S., & Kennedy, S. H. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.1.78 · Cited by 231 · cited 1×
“Additionally, administration of paroxetine downregulates 5-HT2A receptor expression.(26) To date, multiple functional polymorphisms of the HTR2A gene have been identified: a silent point mutation 102T 4 C that is completely linked to a −1438G 4 A promoter polymorphism, and a polymorphism in the coding region causing a…”
Somatic Symptoms in Children and Adolescents With Anxiety Disorders
GINSBURG, G. S., RIDDLE, M. A., & DAVIES, M. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000231974.43966.6e · Cited by 193
Strawn, J. R., Welge, J. A., Wehry, A. M., Keeshin, B., & Rynn, M. A. (2015) · Depression and Anxiety · doi:10.1002/da.22329 · Cited by 183
Self-citationAmphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents
Punja, S., Shamseer, L., Hartling, L., Urichuk, L., Vandermeer, B., Nikles, J., & Vohra, S. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009996.pub2 · Cited by 122
Cited by
Evidence-based pharmacological treatment options for ADHD in children and adolescents
Mechler, K., Banaschewski, T., Hohmann, S., & Häge, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107940 · Cited by 293
Research Review: Pediatric Anxiety Disorders—What Have We Learnt in the Last 10 Years?
Strawn, J. R., Lu, L., Peris, T. S., Levine, A., & Walkup, J. T. (2021) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.13262 · Cited by 168
Self-citationQuintero, J., Gutiérrez-Casares, J. R., & Álamo, C. (2022) · Neurology and Therapy · doi:10.1007/s40120-022-00392-2 · Cited by 70
Elsayed, N. A., Yamamoto, K. M., & Froehlich, T. E. (2020) · CNS Drugs · doi:10.1007/s40263-020-00702-y · Cited by 23
Metadata
- Authors
- Wehry, A. M., Ramsey, L., Dulemba, S. E., Mossman, S. A., & Strawn, J. R.
- Venue
- Current Problems in Pediatric and Adolescent Health Care
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 48
- Issue
- 2
- Pages
- 40-49
- ISSN
- 1538-3199 (ISSN-L)
- 1538-5442
- OpenAlex
- W2785544881
- Cited by
- 62
- References
- 11
- FWCI
- 9.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacogenomic Testing in Child and Adolescent Psychiatry: An Evidence-Based Review. https://app.cochat.ai/papers/10.1016/j.cppeds.2017.12.003
- The paper
- Wehry, A. M., Ramsey, L., Dulemba, S. E., Mossman, S. A., & Strawn, J. R. (2018). Pharmacogenomic Testing in Child and Adolescent Psychiatry: An Evidence-Based Review. Current Problems in Pediatric and Adolescent Health Care. https://doi.org/10.1016/j.cppeds.2017.12.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.